Skip to content

Development of an AAV-Encoded Adenine Base Editor for Duchenne Muscular Dystrophy.

Sep 2026 · Human Gene Therapy · pp. 10430342261486117 · 0 citations · 38 references
Medicine

TL;DR

It is suggested that even modest levels of base editing-mediated exon skipping may ameliorate the DMD cardiac phenotype toward a BMD-like state, supporting the translational potential of this dual rAAV base editing approach for DMD cardiomyopathy.

Abstract

Duchenne muscular dystrophy (DMD) is a devastating X-linked disorder caused by out-of-frame mutations in the DMD gene, most commonly large deletions or duplications, as well as nonsense and splice site mutations, that result in the absence of functional dystrophin protein. These mutations lead to progressive skeletal and cardiac muscle failure. In particular, exon 52 of the DMD gene represents a mutational hotspot in DMD patients. Deletion of exon 52 (DMDΔ52) disrupts the reading frame, leading to premature termination of translation. Here, we used a dual recombinant adeno-associated virus (rAAV) system employing an intein-mediated split strategy to deliver ABE8e using the PAM-less SpRY Cas9 nickase for adenine base editing of splice acceptor sites (SAS) in the dystrophin gene. Targeting the SAS of exon 51 or exon 53 in a DMDΔ52 background aims to induce exon skipping, thereby restoring the open reading frame, in effect converting the severe DMD phenotype into a milder Becker muscular dystrophy (BMD)-like phenotype. We systematically screened sgRNAs in porcine kidney fibroblasts and human embryonic kidney cells (HEK293T), identifying a guide RNA targeting the SAS of exon 53 as the most effective candidate with high on-target editing efficacies and minimal bystander editing. In human DMDΔ52 iPSC-derived cardiomyocytes cultivated as 2D monolayers, high editing efficiencies were achieved with the optimized 1:2 ratio of N-Terminus to C-Terminus. Functional assessment in 3D engineered heart patches revealed a trend toward normalization of the arrhythmic DMD phenotype with an increase in the effective refractory period (ERP) and a reduction in arrhythmic load compared with untreated DMD patches, despite lower editing efficacy in the 3D setting. These findings suggest that even modest levels of base editing-mediated exon skipping may ameliorate the DMD cardiac phenotype toward a BMD-like state, supporting the translational potential of this dual rAAV base editing approach for DMD cardiomyopathy.

View source

Similar papers

Open access Sep 2026

RNA trans-splicing treatment for Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a fatal disorder caused by dystrophin mutations, leading to progressive muscle degeneration and cardiac failure. Although AAV-based DMD therapies with innovative designs to overcome the cargo limits of the virus are effective in animal models, these current systems may face clinical...

Ryan H. Hsu, Claire E. Williams, Geraldine Maier et al. · 0 citations
#gene editing Sep 2026

Novel Therapeutic Frontiers in Duchenne Muscular Dystrophy: Gene Therapy, Exon Skipping, and Stem Cell Approaches.

Through multidisciplinary treatment and continuous scientific progress, individualized precision medicine that integrates therapies targeting secondary pathogenic pathways with dystrophin-restoration techniques can finally convert this devastating illness into a tolerable chronic ailment.

Shahjad Ansari, Mohd Amaan Saifi, Sarfaraz Ahmed et al. · 0 citations
Open access Sep 2026

Engineering suppressor tRNAs for effective treatment of Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a fatal disorder caused by loss of dystrophin, a protein essential for muscle cell integrity. To date, no therapeutic has restored full-length dystrophin. Suppressor transfer RNAs (sup-tRNAs) have the potential to treat the ∼15% of patients with DMD and nonsense mutations. We have e...

Julien Oury, Ying-Hsin Chen, Sean Mcfarland et al. · 0 citations

Advancing adeno-associated virus (AAV) gene therapy for Duchenne muscular dystrophy

A human skeletal muscle xenograft model is adapted, using 222 transplanted muscles from human donors, to use as a platform for AAV delivery and shows for the first time, that human muscles transplanted in immune-deficient mice are efficiently transduced by AAV vectors at following intravenous injection of the host mice...

Matthew J Burke · 0 citations
Review Sep 2026

CRISPR Gene Editing Could Cure Duchenne Muscular Dystrophy but Fatal AAV Immune Responses Remain Unresolved

Duchenne muscular dystrophy (DMD) remains, despite decades of careful clinical management, a relentless disease - and for a long time, medicine could only slow it down, not stop it. That may be changing. CRISPR-Cas genome editing now offers something earlier therapies could not: a route to permanent, DNA-level correcti...

Unknown authors · 0 citations

Related blog posts

Google DeepMind Blog Sep 30, 2026

Introducing SynthID Bio

Proof of concept for watermarking AI-generated proteins while preserving biological function.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.